Advertisement

Topics

BioTime, Inc.  Company Profile

09:28 EDT 14th August 2018 | BioPortfolio

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell and drug delivery. Its clinical programs are based on two platform technologies: pluripotent cells, which can become any type of cell in the human body, and cell/drug delivery. Renevia®, a cell delivery product, met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients earlier this year. Submission for approval of Renevia® in the EU is expected to be early 2018, with possible approval and commercial launch in 2018. There were no device related serious adverse events reported. OpRegen®, a retinal pigment epithelium transplant therapy, is in a Phase I/IIa multicenter trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no related serious adverse events reported. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.


News Articles [46 Associated News Articles listed on BioPortfolio]

BioTime erhält Zuschuss in Höhe von 1,9 Millionen US-Dollar für Weiterentwicklung von OpRegen für Dry-AMD

BioTime, Inc. (NYSE American: BTX), ein klinisches Biotechnologie-Unternehmen, das sich auf degenerative Erkrankungen spezialisiert, hat von der Israel Innovation Authority (IIA) für das Jahr 2018...

Biotechnology firm BioTime to secure $43m from Juvenescence

Under the terms of the agreement, Juvenescence will purchase, in a single transaction, 14.4 million shares of AgeX Therapeutics from BioTime for $43.2 million. 50% of the purchase The post Biotechnol...

BioTime Announces $1.9 Million Grant for Continued Development of OpRegen for Dry-AMD

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approxi...

BioTime to Present at the 8th Annual LD Micro Invitational

BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer of BioT...

BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018

BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Adi...

A Look At BioTime: Part 1 - Introduction And Renevia

BioTime's Dry AMD Product OpRegen: A Look At Trial Data

BioTime, Inc.: An Undervalued Regenerative Medicine Company

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [8 Associated Companies listed on BioPortfolio]

BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell techn...

BioTime, Inc. and Abcodia Ltd.

BioTime is a biotechnology company engaged in research and product development in the field of regenerative medicine. Regenerative medicine refers to therapies based on stem cell ...

BioTime, Inc. 

BioTime is a late stage clinical biotechnology company focused on developing and commercializing products addressing degenerative diseases. The Company’s current clinical ...

BioTime Incorporated

BioTime, Inc. (OTCBB: BTIM), based in Emeryville, California, is engaged in the research and development of aqueous-based synthetic solutions that may be used as plasma expanders, organ preservation s...

AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE MKT:BTX), is a biotechnology company applying technology relating to cell immortality and regenerative biology, to agi...

More Information about "BioTime, Inc. " on BioPortfolio

We have published hundreds of BioTime, Inc.  news stories on BioPortfolio along with dozens of BioTime, Inc.  Clinical Trials and PubMed Articles about BioTime, Inc.  for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioTime, Inc.  Companies in our database. You can also find out about relevant BioTime, Inc.  Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Delivery
<!--LGfEGNT2Lhm-->Drug delivery is the method or process of administering a pharmaceutical compound to achieve a therapeutic effect in humans or animals.  <!--LGfEGNT2Lhm-->Drug delivery technologies are <!--LGfEGNT2Lhm-->patent pr...


Corporate Database Quicklinks



Searches Linking to this Company Record